p38a (T106M)

MAPK14 · Variant type: point · HGVS: p.T106M

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ponatinib	81.0%	19.0%	78.23
2	Cabozantinib	50.3%	49.7%	92.73
3	Tivozanib	39.4%	60.6%	92.42
4	Sorafenib	34.7%	65.3%	96.72
5	Ripretinib	32.9%	67.1%	92.95
6	Regorafenib	30.9%	69.1%	95.99
7	Rabusertib	20.2%	79.8%	98.74
8	Brigatinib	18.4%	81.6%	82.96
9	Lenvatinib	17.0%	83.0%	97.74
10	Upadacitinib	16.8%	83.2%	97.98
11	Apatinib	15.4%	84.6%	97.73
12	Tepotinib	13.2%	86.8%	99.75
13	Paxalisib	12.9%	87.1%	99.75
14	Deucravacitinib	12.7%	87.3%	98.99
15	Selumetinib	11.4%	88.6%	100.00
16	Ceritinib	11.0%	89.0%	95.44
17	Defactinib	10.9%	89.1%	92.68
18	Alectinib	9.2%	90.8%	95.49
19	Leniolisib	7.7%	92.3%	100.00
20	Selpercatinib	6.9%	93.1%	96.72
21	Abemaciclib	6.7%	93.3%	91.48
22	Ruxolitinib	6.3%	93.7%	98.25
23	Infigratinib	6.1%	93.9%	98.24
24	Erdafitinib	6.1%	93.9%	95.71
25	Neratinib	5.6%	94.4%	93.18

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ponatinib	81.0%	—	—
Cabozantinib	50.3%	—	—
Tivozanib	39.4%	—	—
Sorafenib	34.7%	—	—
Ripretinib	32.9%	—	—
Regorafenib	30.9%	—	—
Rabusertib	20.2%	—	—
Brigatinib	18.4%	—	—
Lenvatinib	17.0%	—	—
Upadacitinib	16.8%	—	—
Apatinib	15.4%	—	—
Tepotinib	13.2%	—	—
Paxalisib	12.9%	—	—
Deucravacitinib	12.7%	—	—
Selumetinib	11.4%	—	—
Ceritinib	11.0%	—	—
Defactinib	10.9%	—	—
Alectinib	9.2%	—	—
Leniolisib	7.7%	—	—
Selpercatinib	6.9%	—	—
Abemaciclib	6.7%	—	—
Ruxolitinib	6.3%	—	—
Infigratinib	6.1%	—	—
Erdafitinib	6.1%	—	—
Neratinib	5.6%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.3ms